---
---

# 21 U.S.C., USLM ref /us/usc/t21/s356–1

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s356.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s356a.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs356%E2%80%931)

## § 356–1. Accelerated approval of priority countermeasures

    (a) __In general__ 

    The Secretary of Health and Human Services may designate a priority countermeasure as a fast-track product pursuant to [section 356 of this title][/us/usc/t21/s356] or as a device granted review priority pursuant to [section 360e(d)(5) of this title][/us/usc/t21/s360e/d/5]. Such a designation may be made prior to the submission of—

        (1) a request for designation by the sponsor or applicant; or

        (2) an application for the investigation of the drug under [section 355(i) of this title][/us/usc/t21/s355/i] or [section 262(a)(3) of title 42][/us/usc/t42/s262/a/3].

        Nothing in this subsection shall be construed to prohibit a sponsor or applicant from declining such a designation.

    (b) __Use of animal trials__ 

        A drug for which approval is sought under [section 355(b) of this title][/us/usc/t21/s355/b] or [section 262 of title 42][/us/usc/t42/s262] on the basis of evidence of effectiveness that is derived from animal studies pursuant to section 123  <sup>\[1\]</sup>  <sup><sup> 1 See References in Text note below. </sup></sup>  may be designated as a fast track product for purposes of this section.

    (c) __Priority review of drugs and biological products__ 

        A priority countermeasure that is a drug or biological product shall be considered a priority drug or biological product for purposes of performance goals for priority drugs or biological products agreed to by the Commissioner of Food and Drugs.

    (d) __Definitions__ 

    For purposes of this title: 1

        (1) The term “priority countermeasure” has the meaning given such term in section 247d–6(h)(4) 1 of title 42.

        (2) The term “priority drugs or biological products” means a drug or biological product that is the subject of a drug or biologics application referred to in section 101(4) of the Food and Drug Administration Modernization Act of 1997.

([Pub. L. 107–188, title I][/us/pl/107/188/tI], § 122, June 12, 2002, [116 Stat. 613][/us/stat/116/613].)

 __References in Text__ 

    Section 123, referred to in subsec. (b), is [section 123 of Pub. L. 107–188][/us/pl/107/188/s123], title I, June 12, 2002, [116 Stat. 613][/us/stat/116/613], which is not classified to the Code.

    This title, referred to in subsec. (d), is title I of [Pub. L. 107–188][/us/pl/107/188], June 12, 2002, [116 Stat. 596][/us/stat/116/596], which enacted this section, [section 669a of Title 29][/us/usc/t29/s669a], Labor, and sections 244, 245, 247d–3a, 247d–3b, 247d–7a to 247d–7d, 300hh, 300hh–11 to 300hh–13, 1320b–5, and 7257d of Title 42, The Public Health and Welfare, amended sections 247d to 247d–6, 264, 266, 290hh–1, and 5196b of Title 42, and enacted provisions set out as notes preceding [section 8101 of Title 38][/us/usc/t38/s8101], Veterans’ Benefits, and under sections 201, 244, 247d, 247d–6, 300hh, 300hh–12, and 1320b–5 of Title 42. For complete classification of this title to the Code, see Tables.

    [Section 247d–6(h)(4) of title 42][/us/usc/t42/s247d–6/h/4], referred to in subsec. (d)(1), was redesignated section 247d–6(e)(4) by [Pub. L. 109–417, title III][/us/pl/109/417/tIII], § 304(3), Dec. 19, 2006, [120 Stat. 2861][/us/stat/120/2861].

    Section 101(4) of the Food and Drug Administration Modernization Act of 1997, referred to in subsec. (d)(2), is [section 101(4) of Pub. L. 105–115][/us/pl/105/115/s101/4], which is set out as a note under [section 379g of this title][/us/usc/t21/s379g].

 __Codification__ 

    Section was enacted as part of the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, and not as part of the Federal Food, Drug, and Cosmetic Act which comprises this chapter.

----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s356.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s356a.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs356%E2%80%931)

----------
----------

[/us/usc/t21/s356]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs356
[/us/usc/t21/s360e/d/5]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs360e%2Fd%2F5
[/us/usc/t21/s355/i]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355%2Fi
[/us/usc/t42/s262/a/3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs262%2Fa%2F3
[/us/usc/t21/s355/b]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355%2Fb
[/us/usc/t42/s262]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs262
[/us/pl/107/188/tI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F107%2F188%2FtI
[/us/stat/116/613]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F116%2F613
[/us/pl/107/188/s123]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F107%2F188%2Fs123
[/us/stat/116/613]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F116%2F613
[/us/pl/107/188]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F107%2F188
[/us/stat/116/596]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F116%2F596
[/us/usc/t29/s669a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft29%2Fs669a
[/us/usc/t38/s8101]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft38%2Fs8101
[/us/usc/t42/s247d–6/h/4]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs247d%E2%80%936%2Fh%2F4
[/us/pl/109/417/tIII]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F109%2F417%2FtIII
[/us/stat/120/2861]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F120%2F2861
[/us/pl/105/115/s101/4]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F105%2F115%2Fs101%2F4
[/us/usc/t21/s379g]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs379g


